If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-11. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Other sources have defined deficiency as less than 25 nmol/L, insufficiency as 30–50 nmol/L and a level for "optimal" intake remains controversial and under research, as of 2026. Part of the controversy is because studies have reported differences in serum levels of 25(OH)D between ethnic groups, with studies pointing to genetic as well as environmental reasons behind these variations. African-American populations have lower serum 25(OH)D than their age-matched white population, but at all ages have superior calcium absorption efficiency, a higher bone mineral density, and as elderly, a lower risk of osteoporosis and fractures. Using the 25(OH)D assay as a screening tool of the generally healthy population to identify and treat individuals is considered not as cost-effective as a government-mandated fortification program. Instead, there is a recommendation that testing should be limited to those showing symptoms of vitamin D deficiency or who have health conditions known to cause vitamin deficiency.
Psychological Types—a framework for consciously orienting psychotherapists to patients by raising particular modes of personality to consciousness and differentiation between analyst and patient. Shadow—(archetype) the repressed, therefore unknown, aspects of the personality, including those often considered to be negative. Self—(archetype) the central overarching concept governing the individuation process, as symbolized by mandalas, the union of male and female, totality, and unity. Jung viewed it as the psyche's central archetype. Synchronicity—an acausal principle as a basis for the apparently random concurrence of phenomena.
== Manufacture == The Meningitis Vaccine Project partnered with SynCo Bio Partners, a Dutch biotech company, and the US government's Center for Biologics Evaluation and Research to develop MenAfriVac, and the Serum Institute of India to manufacture it. MenAfriVac is a freeze-dried vaccine of a polysaccharide from a type of Neisseria meningitidis called group A. The polysaccharide has been purified by affinity chromatography and bound to a carrier protein called tetanus toxoid (TT). The TT is prepared by extraction by ammonium sulfate precipitation and the toxin is inactivated with formalin from cultures of Clostridium tetani grown in a modified Mueller–Hinton agar.
Inuit snow goggles – the Inuit made snow goggles which protected their eyes against the harsh winds in the Arctic regions of North America, long before sunglasses became available to modern Europeans.
NAD(P)H dehydrogenase [quinone] 1 is an enzyme that in humans is encoded by the NQO1 gene. This protein-coding gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a 2-electron reductase (enzyme). This FAD-binding protein forms homodimers and performs two-electron reduction of quinones to hydroquinones and of other redox dyes. It has a preference for short-chain acceptor quinones, such as ubiquinone, benzoquinone, juglone and duroquinone. This gene has an important paralog NQO2. This protein is located in the cytosol. NQO1 enzyme expression can be induced by dioxin and inhibited by dicoumarol.
Sources: en.wikipedia.org
== See also == Better Life Index Broad measures of economic progress Gross National Happiness Gross National Well-being Happiness economics Human Development Index Humanistic economics Job satisfaction Social determinants of health Social determinants of health in poverty Social determinants of mental health World Values Survey
This interaction allows violet seed to germinate and establish in a protected, stable environment. Many violet seeds exhibit physiological dormancy and require some period of cold stratification to induce germination under ex situ conditions. Rates of germination are often quite poor, especially when seeds are stored for extended periods of time. In North American habitat restoration, native violets are in high demand due to their relationship with the aforementioned fritillary butterflies. Violet species occupy a diverse array of habitats, from bogs (Viola lanceolata) to dry hill prairies (V. pedata) to woodland understories (V. labradorica). While many of these species are indicators of high quality habitat, some violets are capable of thriving in a human altered landscape. Two species of zinc violet (V. calaminaria and V. guestphalica) are capable of living in soils severely contaminated with heavy metals. Many violets form relationships with arbuscular mycorrhizal fungi, and in the case of the zinc violets, this allows them to tolerate such highly contaminated soils. Flowering is often profuse, and may last for much of the spring and summer. Viola are most often spring-blooming with chasmogamous flowers that have well-developed petals pollinated by insects. Many species also produce self-pollinated cleistogamous flowers in summer and autumn that do not open and lack petals. In some species the showy chasmogamous flowers are infertile (e.g.,Viola sororia).
=== In vitro virus high-throughput sequencing === A method has been developed to analyze full sets of protein interactions using a combination of 454 pyrosequencing and an in vitro virus mRNA display method. Specifically, this method covalently links proteins of interest to the mRNAs encoding them, then detects the mRNA pieces using reverse transcription PCRs. The mRNA may then be amplified and sequenced. The combined method was titled IVV-HiTSeq and can be performed under cell-free conditions, though its results may not be representative of in vivo conditions.
As one of the largest cities in the Southern Appalachian region, Knoxville had long been a nexus between the surrounding rural mountain hinterland and the major industrial centers of the North, and thus had long been home to a thriving wholesaling (or "jobbing") market. Rural merchants from across East Tennessee purchased goods for their general stores from Knoxville wholesalers. With the arrival of the railroad, the city's wholesaling sector expanded rapidly, with over a dozen firms in operation by 1860, and 50 by 1896. In 1866, Knoxville-based wholesaler Cowan, McClung and Company was the most profitable company in the state. By the late-1890s, Knoxville had the third-largest wholesaling market in the South. The railroad also led to a boom in the quarrying and production of Tennessee marble, a type of crystalline limestone found in abundance in the ridges surrounding Knoxville. By the early 1890s, twenty-two quarries and three finishing mills were in operation in Knox County alone, and the industry as a whole was generating over a million dollars in annual profits. Tennessee marble was used in monumental construction projects across the nation, earning Knoxville the nickname, "The Marble City," during the late 19th century. The Flag of Knoxville, Tennessee incorporates the color white to symbolize marble and displays a derrick used in marble mining.
Transparency of information is another factor defining a delivery system. Access to information on conditions, treatments, quality, and pricing greatly affects the choice of patients/consumers and, therefore, the incentives of medical professionals. While the US healthcare system has come under fire for its lack of openness, new legislation may encourage greater openness. There is a perceived tension between the demand for transparency and concerns over patient confidentiality and the commercial misuse of medical data. Advocates argue that openness helps patients make informed decisions, while critics warn it can expose sensitive records and invite exploitation by insurers, employers, or marketers. Balancing accountability with privacy remains a central challenge. The health professionals who provide care in medicine comprise multiple professions, such as medics, nurses, physiotherapists, and psychologists. These professions will have their own ethical standards, professional education, and bodies. The medical profession has been conceptualized from a sociological perspective.
Sources: en.wikipedia.org
== Progenotes == Progenotes (also called ribocytes or ribocells) are open or semi-open biological systems capable of intensely exchanging genetic information, before the existence of cells and LUCA. The term progenote was coined by Carl Woese in 1977, around the time he introduced the concept of the three domains of life (bacteria, archaea, and eukaryotes). Woese also proposed that each domain originated from a different progenote. The meaning of progenote changed over time, when in the 1980s, Doolittle and Darnell used the term to refer to the single ancestor of all three domains of life, now referred to as the last universal common ancestor (LUCA). The terms ribocyte and ribocell refer to progenotes as early forms of ribosomes (protoribosomes), hypothetical primitive cellular organisms with self-replicating RNA with an RNA genome instead of the usual DNA genome. In Carl Woese's Darwinian threshold period of cellular evolution, progenotes are also thought to have had RNA rather than DNA as informational molecule. The evolution of the ribosome from ancient ribocytes, the self-replicating RNA systems and machinery, into its current form as a translation machine may have been the selective pressure to then incorporate proteins into the ribosome's self-replicating mechanisms, which would increase its capacity to self-replicate. Ribosomal RNA is thought to have emerged before cells or viruses, during the time when progenotes existed. Progenotes both composed FUCA and descended from FUCA.
== Turbidity tests == Fibrillogenesis can be analyzed through the use of turbidity tests. Turbidity is way of measuring the haziness, cloudiness, or fogginess of sample and also can be used to test the light-scattering properties of said sample. A turbidity test on fibrillogenesis will start with a sample of collagen triple-helices, which will have a low-level of turbidity. After fibrillogenesis is completed, the triple-helices will have formed fibrils. A sample of fibrils will have a high-level of turbidity when compared to that of a sample of triple-helices. As fibrillogenesis is taking place, there is a change in the light-scattering properties of the sample over time, which can be measured with a spectrophotometer. The wavelength typically used to measure fibrillogenesis with a spectrophotometer ranges from 310nm to 313nm. Turbidity tests done on type I collagen triple-helices will display a sigmoidal curve when plotted on a graph. The sigmoidal curve is divided into three phases; lag phase, growth phase, and plateau phase.
== Usefulness of NTX as a biomarker == Evaluating an individual's rate of bone turnover, termed bone remodeling, directly may be important in assessing his or her potential nonsurgical treatment response as well as evaluating his or her risk of developing complications during healing following surgical intervention. To determine an individual's rate of bone turnover, numerous biomarkers are available in the body fluids that can be correlated to this rate, and one such biomarker is NTX. However, while NTX does fluctuate in a very sensitive manner in line with bone resorption patterns, they are not very specific, in that they may vary spontaneously without physiologic intervention. For example, NTX levels may drop by 50% from day to day with no treatment, thus, making NTX levels unconvincing evidence of treatment effect. Conversely, the serum CTX biomarker, described in 2000 by Rosen, appears to be a much more effective and valuable indicator of bone resorption rate.
=== Kyphoscoliosis === Kyphoscoliosis EDS (kEDS; formerly categorized as type 6) is associated with severe hypotonia at birth, delayed motor development, progressive scoliosis (present from birth), and scleral fragility. People may also have easy bruising, fragile arteries that are prone to rupture, unusually small corneas, and osteopenia (low bone density). Other common features include a "marfanoid habitus" characterized by long, slender fingers (arachnodactyly), unusually long limbs, and a sunken chest (pectus excavatum) or protruding chest (pectus carinatum). It can be caused by variations in the gene PLOD1, or rarely, in the FKBP14 gene.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.